LittleGunner retweeted
Also means that multiple, senior, powerful people committed perjury at CAS.
@fedpolCH get busy.
LittleGunner retweeted
🚨 EXCLUSIVE: Manchester City found guilty on virtually all charges relating to breaches of Premier League financial regulations. #MCFC expected to appeal against verdict issued by independent commission. Sanctions undecided, process ongoing @TheAthleticFC nytimes.com/athletic/7049721…
LittleGunner retweeted
So today's data confirms 6k is still effective in SGC. But more importantly, below we have it (mistakenly) from the horses mouth that they're talking to Norvartis. It's always been about that PLATFORM. Stupid drop today, but not for long #AVCT – at Cape Canaveral, FL
This Post is from an account that no longer exists. Learn more
LittleGunner retweeted
#AVCT As I said, and as everyone knows! The science is great, we get it! We want to know how you're going to commercialise it and what the commercial road map looks like.
Read the room @coughlin582 @avacta! The SP is where it is because of this. Talk commercial, not science!
#AVCT @coughlin582
If you think you can pay the next CLN in shares but the SP will recover because of anything science based you release at AACR, you are MISTAKEN
A commercial plan is reqd which YOU highlighted as priority 12 mnths ago!
The science aint cutting it, unfortunately!
LittleGunner retweeted
#AVCT
Shorters are clearly back..🤔
Just sign us a small deal ffs. Third party validation is needed
Ignore the 50 billion dollar value crowd
...just get us a partner who see the value in this safe and superior delivery platform to a pipeline of oncology weapons
Get on with it
LittleGunner retweeted
Replying to @RAH00084 @111BEN_111
There’s 10s of deals being struck that underpin this. Can management get this under the nose of those with similar cash piles? Can they sell the upside story?
It’s all getting a bit silly.
Asthma 🤚🏻#AVCT
$40m upfront.
14.3m warrants (19.9% stock)
$940m milestone out turn.
Asthma target.
1x 22 patient Phase 2a asset.
1x preclinical asset.
“Further validates platform”
CEO confirmed deal discussions were progressing in April ‘24. Tuned in. #AVCT
LittleGunner retweeted
Final sentence of each paragraph #avct
LittleGunner retweeted
Replying to @tom_the_bomb__
#avct attendance focus set on ‘investment’ rather than an opportunity to share trial results…. That’s how I read it.
Questions is, are they using this event to:
1) Entice partners,
2) Announce partner,
3) Both
voxmarkets.co.uk/rns/announc…
The most important milestone that is now covered off.
Switch off, ignore the hash tag, the trolls and the fawning.
The science has never been in question. See you in 9 months.
#AVCT
voxmarkets.co.uk/rns/announc…
At last this complete sh*it show of an idea is starting to be reversed and the company add the all important cash to the bank which will lead to the P1b data read outs late in the year.
Coris still to divest for an expected few £mil to again
1/2
#AVCT
5
42
6,281
voxmarkets.co.uk/rns/announc…
At last this complete sh*it show of an idea is starting to be reversed and the company add the all important cash to the bank which will lead to the P1b data read outs late in the year.
Coris still to divest for an expected few £mil to again
1/2
#AVCT
Help push the company over the line to the most important milestone.
HCI will have to remain as an annoying itch that can't be scratched for now. We must live with the dumping knowing what reward we will get for that pain.
A sorry chapter but we can at last look forward
#AVCT
1
32
1,410
LittleGunner retweeted
Finally it's (almost) gone! The long and sorry episode which got us lumbered with the CLN is over. Enough cash to see us into 2026 and to get enough P1b data to sign a phenomenal deal or get taken out. Sell Coris for a couple of mil as well then chase the TX dream #AVCT – at Exeter, England
Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update. avacta.com/avacta-announces-… #AVCT
LittleGunner retweeted
Tell me you don’t get it without telling me you don’t get it 🤦♂️
The biggest risk facing #avct shareholders is the funding strategy. It’s not the science


























